Healthline

Zeposia and Cost: What You Need to Know

The price you pay for Zeposia (ozanimod) may depend on factors such as whether you have health insurance and the pharmacy you use. Financial assistance may be available to help with the cost. The ...
Healthline

Zeposia and Its Use for Treating Multiple Sclerosis

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...
Medical News Today

Zeposia and pregnancy, breastfeeding, and birth control

Zeposia (ozanimod) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can take the drug during this time. If you may be ...
FiercePharma

Bristol Myers Squibb's Zeposia boosts remission rates over placebo in ulcerative colitis patients

As one of the hottest markets in pharmaceuticals, immunology has become a murderers' row of blockbuster drugs in recent years. But Bristol Myers Squibb has big hopes for a next-gen entry in Zeposia, ...
Medscape

FDA Approves Ozanimod (Zeposia) for Ulcerative Colitis

The US Food and Drug Administration (FDA) has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced. Ozanimod (0.92 mg), an oral ...
Healio

FDA approves Zeposia for moderate-to-severe ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...
Healio

Q&A: Zeposia may be efficacious oral therapy for UC

Please provide your email address to receive an email when new articles are posted on . Zeposia may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ...
Yahoo Finance

Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis

Bristol-Myers Squibb Company BMY announced that the FDA has granted approval to its sphingosine-1-phosphate (S1P) receptor modulator Zeposia (ozanimod) for the treatment of adult patients with ...
PharmaTimes

NICE no for BMS’ multiple sclerosis drug Zeposia

The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s (BMS) Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In an ...
Nasdaq

Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study

Bristol-Myers Squibb Company BMY announced positive topline data from the pivotal phase III True North study, which evaluated its newly-approved multiple sclerosis drug Zeposia (ozanimod) for a new ...
FiercePharma

Bristol Myers Squibb's Zeposia, AbbVie's Skyrizi and Rinvoq shake up early IBD treatment market: report

The U.S. inflammatory bowel disease (IBD) market is seeing a shift in what drugs patients are offered for their first prescriptions. Doctors appear to be favoring the most recently approved drugs from ...